Terms: = Lymphoma AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Prognosis
19 results:
1. Key candidate genes and pathways in T lymphoblastic leukemia/lymphoma identified by bioinformatics and serological analyses.
Ren Y; Liang H; Huang Y; Miao Y; Li R; Qiang J; Wu L; Qi J; Li Y; Xia Y; Huang L; Wang S; Kong X; Zhou Y; Zhang Q; Zhu G
Front Immunol; 2024; 15():1341255. PubMed ID: 38464517
[TBL] [Abstract] [Full Text] [Related]
2. Proteomics Identifies Circulating timp-1 as a Prognostic Biomarker for Diffuse Large B-Cell lymphoma.
Lou N; Wang G; Wang Y; Xu M; Zhou Y; Tan Q; Zhong Q; Zhang L; Zhang X; Liu S; Luo R; Wang S; Tang L; Yao J; Zhang Z; Shi Y; Yu X; Han X
Mol Cell Proteomics; 2023 Sep; 22(9):100625. PubMed ID: 37500057
[TBL] [Abstract] [Full Text] [Related]
3. BCR-ABL1-like B-Lymphoblastic Leukemia/lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
Yenamandra AK; Kaviany S; Borinstein SC; Friedman DL; Kovach AE
Lab Med; 2019 Oct; 50(4):401-405. PubMed ID: 30938769
[TBL] [Abstract] [Full Text] [Related]
4. Invasion-associated genes identified by gene expression profiling in extranodal natural killer/T-cell lymphoma, nasal type.
Yu JB; Zhang YC; Yang QP; Wang XL; Tang Y; Zhao S; Mo XM; Liu WP
Leuk Lymphoma; 2013 Jan; 54(1):90-8. PubMed ID: 22680768
[TBL] [Abstract] [Full Text] [Related]
5. Matrix metalloproteinase-2 promoter and tissue inhibitor of metalloproteinase-2 gene polymorphisms in non-Hodgkin's lymphoma.
Diao LP; Ma H; Wei GC; Li T; Liu HS; Liu LH; Wu LL; Zhao GM; Gao YH
Int J Cancer; 2012 Sep; 131(5):1095-103. PubMed ID: 22020421
[TBL] [Abstract] [Full Text] [Related]
6. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
Durmaz O; Demirkaya M; Sevinir B
Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
[TBL] [Abstract] [Full Text] [Related]
7. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.
Schrötzlmair F; Kopitz C; Halbgewachs B; Lu F; Algül H; Brünner N; Gänsbacher B; Krüger A
J Cell Mol Med; 2010 Dec; 14(12):2760-70. PubMed ID: 19863693
[TBL] [Abstract] [Full Text] [Related]
8. Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
Kyllönen H; Pasanen AK; Kuittinen O; Haapasaari KM; Turpeenniemi-Hujanen T
Leuk Lymphoma; 2009 Aug; 50(8):1301-7. PubMed ID: 19811332
[TBL] [Abstract] [Full Text] [Related]
9. Expression of the metalloproteases MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, timp-1 and timp-2 in angiocentric midfacial lymphomas.
Meneses-García A; Betancourt AM; Abarca JH; Montes AB; Roa LS; Ruíz-Godoy L
World J Surg Oncol; 2008 Oct; 6():114. PubMed ID: 18954439
[TBL] [Abstract] [Full Text] [Related]
10. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (timp-1) in tissues with a diagnosis of childhood lymphoma.
Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
[TBL] [Abstract] [Full Text] [Related]
12. Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma: A report from the children's oncology group.
Nasr MR; Laver JH; Chang M; Hutchison RE
Am J Clin Pathol; 2007 May; 127(5):770-8. PubMed ID: 17439836
[TBL] [Abstract] [Full Text] [Related]
13. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.
Thiele J; Kvasnicka HM
Leuk Lymphoma; 2006 Mar; 47(3):381-96. PubMed ID: 16396760
[TBL] [Abstract] [Full Text] [Related]
14. [Metalloproteinase (MMP-1, 2 and 11), tissue inhibitor of metalloproteinase-1 (timp-1), and p53 expression in nasal-type angiocentric T/NK-cell lymphoma: an immunohistochemical study].
Meneses-García A; Herrera J; Mohar A; García-Cuellar C; Súchil-Bernal L
Gac Med Mex; 2005; 141(4):291-6. PubMed ID: 16164124
[TBL] [Abstract] [Full Text] [Related]
15. Gelatinases (MMP-2 and MMP-9), timp-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas.
Kuittinen O; Apaja-Sarkkinen M; Turpeenniemi-Hujanen T
Eur J Haematol; 2003 Aug; 71(2):91-9. PubMed ID: 12890147
[TBL] [Abstract] [Full Text] [Related]
16. EMMPRIN (CD 147) is expressed in Hodgkin's lymphoma and anaplastic large cell lymphoma. An immunohistochemical study of 60 cases.
Thorns C; Feller AC; Merz H
Anticancer Res; 2002; 22(4):1983-6. PubMed ID: 12174874
[TBL] [Abstract] [Full Text] [Related]
17. Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis.
Guedez L; Mansoor A; Birkedal-Hansen B; Lim MS; Fukushima P; Venzon D; Stetler-Stevenson WG; Stetler-Stevenson M
Blood; 2001 Mar; 97(6):1796-802. PubMed ID: 11238122
[TBL] [Abstract] [Full Text] [Related]
18. The impact and management of anaemia in haematological malignancies.
Coiffier B
Med Oncol; 2000 Nov; 17 Suppl 1():S2-10. PubMed ID: 11188782
[TBL] [Abstract] [Full Text] [Related]
19. Quantitative expression of erythropoietin receptor (epo-R) on acute leukaemia cells: relationships between the amount of epo-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan Adult Leukaemia Study Group.
Takeshita A; Shinjo K; Higuchi M; Miyawaki S; Takemoto Y; Kishimoto Y; Saito K; Takuchi H; Kuriyama K; Kimura Y; Asou N; Takahashi M; Hotta T; Kanamaru A; Ueda R; Ohno R
Br J Haematol; 2000 Jan; 108(1):55-63. PubMed ID: 10651724
[TBL] [Abstract] [Full Text] [Related]
